On June 10, 2008, Daiichi Sankyo agreed to take a majority (35%) stake in Indian generic drug maker Ranbaxy, with a deal valued at about $4.6 billion.
In June 2008, Japan's Daiichi Sankyo Company took a majority (50.1%) stake in Ranbaxy, with a deal valued at about US$4.6 billion.
However a generic version manufactured by Japanese-owned Indian company Daiichi-Ranbaxy was found by the District Court of New Jersey, USA not to infringe Roche's patent.
Some of their renowned landmark buildings include ITC Green Centre, ITC Royal Gardenia, Grand Hyatt, Maurya Sheraton, Corporate offices in Delhi NCR of Ranbaxy, Microsoft & Ericsson etc.
Indian Medical Association 78th National Conference of I.M.A 2003 Ranbaxy Oration.